Abstract
BackgroundAn important factor influencing pharmacokinetics of adalimumab is immunogenicity. There is a dose-dependent effect of methotrexate (MTX) on the amount of anti-drug antibodies produced against adalimumab [1]. Consequently, patients concomitantly...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have